Free Trial
NASDAQ:MGNX

MacroGenics (MGNX) Stock Price, News & Analysis

MacroGenics logo
$1.48 -0.06 (-3.90%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$1.48 +0.01 (+0.34%)
As of 07/18/2025 05:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About MacroGenics Stock (NASDAQ:MGNX)

Key Stats

Today's Range
$1.47
$1.60
50-Day Range
$1.19
$1.78
52-Week Range
$0.99
$5.77
Volume
381,878 shs
Average Volume
836,910 shs
Market Capitalization
$93.37 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.71
Consensus Rating
Hold

Company Overview

MacroGenics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
82nd Percentile Overall Score

MGNX MarketRank™: 

MacroGenics scored higher than 82% of companies evaluated by MarketBeat, and ranked 143rd out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    MacroGenics has received a consensus rating of Hold. The company's average rating score is 2.40, and is based on 2 buy ratings, 7 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    MacroGenics has only been the subject of 3 research reports in the past 90 days.

  • Read more about MacroGenics' stock forecast and price target.
  • Earnings Growth

    Earnings for MacroGenics are expected to decrease in the coming year, from ($1.06) to ($2.06) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of MacroGenics is -1.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of MacroGenics is -1.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    MacroGenics has a P/B Ratio of 0.80. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about MacroGenics' valuation and earnings.
  • Percentage of Shares Shorted

    7.80% of the float of MacroGenics has been sold short.
  • Short Interest Ratio / Days to Cover

    MacroGenics has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in MacroGenics has recently decreased by 18.26%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    MacroGenics does not currently pay a dividend.

  • Dividend Growth

    MacroGenics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    7.80% of the float of MacroGenics has been sold short.
  • Short Interest Ratio / Days to Cover

    MacroGenics has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in MacroGenics has recently decreased by 18.26%, indicating that investor sentiment is improving significantly.
  • MarketBeat Follows

    1 people have added MacroGenics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, MacroGenics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    13.00% of the stock of MacroGenics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    96.89% of the stock of MacroGenics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about MacroGenics' insider trading history.
Receive MGNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MacroGenics and its competitors with MarketBeat's FREE daily newsletter.

MGNX Stock News Headlines

A new rule goes live in July — and the banks are quietly cashing in
A little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them.
MacroGenics: Working On That Road To Recovery
See More Headlines

MGNX Stock Analysis - Frequently Asked Questions

MacroGenics' stock was trading at $3.25 at the beginning of the year. Since then, MGNX shares have decreased by 54.5% and is now trading at $1.48.

MacroGenics, Inc. (NASDAQ:MGNX) announced its earnings results on Tuesday, May, 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing analysts' consensus estimates of ($0.61) by $0.04. The biopharmaceutical company had revenue of $13.19 million for the quarter, compared to analysts' expectations of $9.59 million. MacroGenics had a negative trailing twelve-month return on equity of 59.84% and a negative net margin of 36.23%.

MacroGenics' top institutional shareholders include XML Financial LLC (0.05%) and Public Employees Retirement System of Ohio (0.04%). Insiders that own company stock include Target N V Biotech, Ezio Bonvini, Edward Hurwitz and Jeffrey Stuart Peters.
View institutional ownership trends
.

Shares of MGNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that MacroGenics investors own include NVIDIA (NVDA), Broadcom (AVGO), Invesco QQQ (QQQ), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE) and Jabil (JBL).

Company Calendar

Last Earnings
5/13/2025
Today
7/18/2025
Next Earnings (Estimated)
8/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED PRODUCTS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:MGNX
CIK
1125345
Employees
430
Year Founded
2000

Price Target and Rating

High Price Target
$14.00
Low Price Target
$2.00
Potential Upside/Downside
+286.1%
Consensus Rating
Hold
Rating Score (0-4)
2.40
Research Coverage
10 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.89)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$66.97 million
Net Margins
-36.23%
Pretax Margin
-35.62%
Return on Equity
-59.84%
Return on Assets
-23.45%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.28
Quick Ratio
3.11

Sales & Book Value

Annual Sales
$149.96 million
Price / Sales
0.62
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.85 per share
Price / Book
0.80

Miscellaneous

Outstanding Shares
63,090,000
Free Float
54,888,000
Market Cap
$93.37 million
Optionable
Optionable
Beta
1.59

Social Links

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

This page (NASDAQ:MGNX) was last updated on 7/19/2025 by MarketBeat.com Staff
From Our Partners